It's all very interesting. We should also think about why the FDA went with the 6 month review process rather than the 2 month process. In my view the FDA have already made a positive determination. They have gone with a 6 month review because our new BLA contains new data, the new data not only links old with new product and provides a extra level of potency assay that would limit the BLA to a two month review as per guidelines. It must contain what they consider substantial new data supporting efficacy and safety for the BLA to be given the 6 month review.
The data, Emergency usage in adults.
FDA have ruled that this protocol contains substantial new data supporting approval. We have the data for adults. Could a accelerated approval be also given for adults? This would be one way the FDA could be assured a confirmatory trial in adults. Head to head with Rux. in those that have high MAP scores letting those that have already failed 2nd line therapy access to our product.
- Forums
- ASX - By Stock
- Cell Therapy News/Articles
It's all very interesting. We should also think about why the...
-
- There are more pages in this discussion • 413 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B |
Open | High | Low | Value | Volume |
$1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2482 | $1.45 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.46 | 27045 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2482 | 1.450 |
1 | 2574 | 1.440 |
1 | 15000 | 1.435 |
2 | 11400 | 1.430 |
1 | 15000 | 1.425 |
Price($) | Vol. | No. |
---|---|---|
1.455 | 14000 | 1 |
1.460 | 14000 | 1 |
1.465 | 14000 | 1 |
1.480 | 50134 | 1 |
1.485 | 40331 | 2 |
Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |